Gene Expression Factors Associated with Rubella-Specific Humoral Immunity After a Third MMR Vaccine Dose
Viruses · 2025
DOI: 10.3390/v17091154 ↗Kurz gefasst
Fachartikel in der Zeitschrift Viruses, 2025. Verfasst von Lara I Teodoro und 6 weiteren Autor:innen. Beteiligte Einrichtung: Mayo Clinic Vaccine Research Group, Mayo Clinic, Rochester, MN 55905, USA. Hauptthemen laut MEDLINE: Rubella, Immunity, Humoral, Measles-Mumps-Rubella Vaccine, Rubella virus. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 55 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIH HHS, NIAID NIH HHS, National Institute of Allergy and Infectious Diseases of the National Institutes of Health.
Abstract (Originalsprache)
Rubella is typically a mild viral illness, but it can lead to severe complications when contracted during pregnancy, such as pregnancy loss or developmental defects in the fetus (congenital rubella syndrome). Therefore, it is crucial to develop and maintain protective immunity in women of childbearing age. In this study, we assessed the transcriptional factors associated with rubella-specific immune outcomes (IgG binding antibody and avidity, neutralizing antibody, and memory B cell ELISpot response) following a third MMR vaccine dose in women of reproductive age to identify key factors/signatures impacting the immune response. We identified baseline (Day 0) and differentially expressed (Day 28–Day 0) genes associated with several RV-specific immune outcomes, including the transferrin receptor 2 (TFR2), which is an important factor regulating iron homeostasis and macrophage functional activity, and a close functional homolog of TFR1, the cellular receptor of the New World hemorrhagic fever arenaviruses. We also identified enriched KEGG pathways, “cell adhesion molecules”, “antigen processing and presentation”, “natural killer cell-mediated cytotoxicity”, and “immune network for IgA production”, relevant to immune response priming and immune activation to be associated with RV-specific immune outcomes. This study provides novel insights into potential biomarkers of rubella-specific immunity in women of childbearing age.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Mayo Clinic Vaccine Research Group, Mayo Clinic, Rochester, MN 55905, USA.
- Department of Quantitative Health Sciences, Mayo Clinic, Rochester, MN 55905, USA.
ORCID-Profile: Lara I Teodoro, Inna G Ovsyannikova, Richard B Kennedy
Förderung
- NIH HHS
- NIAID NIH HHS
- National Institute of Allergy and Infectious Diseases of the National Institutes of Health
Zitieren
APA
Teodoro, L. I., Haralambieva, I. H., Ovsyannikova, I. G., Goergen, K. M., Grill, D. E., Poland, G. A., & Kennedy, R. B. (2025). Gene Expression Factors Associated with Rubella-Specific Humoral Immunity After a Third MMR Vaccine Dose. Viruses. https://doi.org/10.3390/v17091154
Vancouver
Teodoro LI, Haralambieva IH, Ovsyannikova IG, Goergen KM, Grill DE, Poland GA, et al. Gene Expression Factors Associated with Rubella-Specific Humoral Immunity After a Third MMR Vaccine Dose. Viruses. 2025. doi:10.3390/v17091154
BibTeX
@article{Teodoro2025,
author = {Teodoro, Lara I and Haralambieva, Iana H and Ovsyannikova, Inna G and Goergen, Krista M and Grill, Diane E and Poland, Gregory A and Kennedy, Richard B},
title = {Gene Expression Factors Associated with Rubella-Specific Humoral Immunity After a Third MMR Vaccine Dose},
journal = {Viruses},
year = {2025},
doi = {10.3390/v17091154}
}
EUVIMED